دورية أكاديمية
أعرض في EDS

Endometrial biomarkers in premenopausal women with obesity: an at-risk cohort.

التفاصيل البيبلوغرافية
العنوان: Endometrial biomarkers in premenopausal women with obesity: an at-risk cohort.
المؤلفون: Dottino JA; Departments of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX., Zhang Q; Departments of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX., Loose DS; Department of Integrative Biology and Pharmacology, University of Texas Health Science Center at Houston, Houston, TX., Fellman B; Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX., Melendez BD; Departments of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX., Borthwick MS; Departments of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX., McKenzie LJ; Departments of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX., Yuan Y; Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX., Yang RK; Departments of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX., Broaddus RR; Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC., Lu KH; Departments of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX., Soliman PT; Departments of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX., Yates MS; Departments of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: msyates@mdanderson.org.
المصدر: American journal of obstetrics and gynecology [Am J Obstet Gynecol] 2021 Mar; Vol. 224 (3), pp. 278.e1-278.e14. Date of Electronic Publication: 2020 Aug 21.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 0370476 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6868 (Electronic) Linking ISSN: 00029378 NLM ISO Abbreviation: Am J Obstet Gynecol Subsets: MEDLINE
أسماء مطبوعة: Publication: <2005->: New York : Elsevier
Original Publication: St. Louis.
مواضيع طبية MeSH: Estrogens/*blood , Obesity/*blood , Premenopause/*blood, Adult ; Biomarkers/blood ; Cohort Studies ; Cross-Sectional Studies ; Endometrial Neoplasms/epidemiology ; Endometrial Neoplasms/etiology ; Endometrium/metabolism ; Endometrium/pathology ; Estrogens/biosynthesis ; Female ; Humans ; Obesity/complications ; Risk Factors
مستخلص: Background: Obesity is a well-known risk factor for endometrial cancer, but the mechanisms of obesity-related carcinogenesis are not well defined, particularly for premenopausal women. With the continuing obesity epidemic, increases in the incidence of endometrial cancer and a younger age of diagnosis are often attributed to a hyperestrogenic state created by hormone production in adipose tissue, but significant knowledge gaps remain. The balance of estrogen-responsive signals has not been defined in the endometrium of premenopausal women with obesity, where obesity may not create hyperestrogenism in the context of ovaries being the primary source of estrogen production. Obesity is associated with a state of low-grade, chronic inflammation that can promote tumorigenesis, and it is also known that hormonal changes alter the immune microenvironment of the endometrium. However, limited research has been conducted on endometrial immune-response changes in women who have an increased risk for cancer due to obesity.
Objective: Endometrial estrogen-regulated biomarkers, previously shown to be dysregulated in endometrial cancer, were evaluated in a cohort of premenopausal women to determine if obesity is associated with differences in the biomarker expression levels, which might reflect an altered risk of developing cancer. The expression of a multiplexed panel of immune-related genes was also evaluated for expression differences related to obesity.
Study Design: Premenopausal women with a body mass index of ≥30 kg/m 2 (n=97) or a body mass index of ≤25 kg/m 2 (n=33) were prospectively enrolled in this cross-sectional study, which included the assessment of serum metabolic markers and a timed endometrial biopsy for pathologic evaluation, hormone-regulated biomarker analysis, and immune response gene expression analysis. Medical and gynecologic histories were obtained. Endometrial gene expression markers were also compared across the body mass index groups in a previous cohort of premenopausal women with an inherited cancer risk (Lynch syndrome).
Results: In addition to known systemic metabolic differences, histologically normal endometria from women with obesity showed a decrease in gene expression of progesterone receptor (P=.0027) and the estrogen-induced genes retinaldehyde dehydrogenase 2 (P=.008), insulin-like growth factor 1 (P=.016), and survivin (P=.042) when compared with women without obesity. The endometrial biomarkers insulin-like growth factor 1, survivin, and progesterone receptor remained statistically significant in multivariate linear regression models. In contrast, women with obesity and Lynch syndrome had an increased expression of insulin-like growth factor 1 (P=.017). There were no differences in endometrial proliferation, and limited endometrial immune differences were observed.
Conclusion: When comparing premenopausal women with and without obesity in the absence of endometrial pathology or an inherited cancer risk, the expression of the endometrial biomarkers does not reflect a local hyperestrogenic environment, but it instead reflects a decreased cancer risk profile that may be indicative of a compensated state. In describing premenopausal endometrial cancer risk, it may be insufficient to attribute a high-risk state to obesity alone; further studies are warranted to evaluate individualized biomarker profiles for differences in the hormone-responsive signals or immune response. In patients with Lynch syndrome, the endometrial biomarker profile suggests that obesity further increases the risk of developing cancer.
(Copyright © 2020 Elsevier Inc. All rights reserved.)
References: Genome Biol. 2002 Jun 18;3(7):RESEARCH0034. (PMID: 12184808)
Immune Netw. 2015 Feb;15(1):16-26. (PMID: 25713505)
JAMA. 2015 Jul 7;314(1):61-71. (PMID: 26151267)
Cancer Prev Res (Phila). 2013 Aug;6(8):774-81. (PMID: 23639481)
J Clin Endocrinol Metab. 2003 May;88(5):2157-63. (PMID: 12727970)
Gut. 2018 Jul;67(7):1306-1316. (PMID: 28754778)
Breast Cancer Res Treat. 2015 Jan;149(1):1-4. (PMID: 25414027)
Clin Cancer Res. 2005 Dec 1;11(23):8258-64. (PMID: 16322283)
Pediatr Nephrol. 2007 Dec;22(12):2011-22. (PMID: 17647026)
Clin Cancer Res. 2006 Nov 1;12(21):6373-8. (PMID: 17085648)
J Clin Endocrinol Metab. 2007 Jul;92(7):2468-73. (PMID: 17440019)
Adv Exp Med Biol. 2017;943:243-259. (PMID: 27910070)
Obstet Gynecol. 2016 Oct;128(4):747-753. (PMID: 27607867)
Mol Cancer Res. 2008 Jun;6(6):1017-28. (PMID: 18567805)
Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19272-7. (PMID: 20974921)
Handb Exp Pharmacol. 2009;(188):197-213. (PMID: 19031027)
J Clin Endocrinol Metab. 2004 Jun;89(6):2622-31. (PMID: 15181033)
Cancer Causes Control. 2016 Jun;27(6):737-48. (PMID: 27125830)
Carcinogenesis. 2018 Sep 21;39(9):1105-1116. (PMID: 29912292)
MMWR Morb Mortal Wkly Rep. 2018 Dec 07;67(48):1333-1338. (PMID: 30521505)
Gynecol Oncol. 2014 Apr;133(1):78-82. (PMID: 24680595)
Endocr Relat Cancer. 2009 Mar;16(1):113-22. (PMID: 18852162)
Cell Immunol. 2009;258(1):18-28. (PMID: 19345936)
Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15847-51. (PMID: 17895382)
J Clin Oncol. 2016 Dec 10;34(35):4270-4276. (PMID: 27903155)
Adv Exp Med Biol. 2017;943:3-46. (PMID: 27910063)
Cell Death Dis. 2010;1:e32. (PMID: 21072319)
Cancer Biol Ther. 2009 Nov;8(22):2126-35. (PMID: 19755863)
J Clin Endocrinol Metab. 2016 Jul;101(7):2883-91. (PMID: 27088794)
Cancer Epidemiol Biomarkers Prev. 2017 May;26(5):727-735. (PMID: 28052940)
Int J Cancer. 2019 Feb 1;144(3):641-650. (PMID: 30289975)
Cell Mol Gastroenterol Hepatol. 2019;8(1):73-94. (PMID: 30878663)
Cancer Res. 1990 May 15;50(10):3019-24. (PMID: 2159368)
Cancer Prev Res (Phila). 2016 Jan;9(1):2-10. (PMID: 26744449)
Reprod Sci. 2015 Jul;22(7):814-28. (PMID: 25634912)
Int J Gynaecol Obstet. 2015 Dec;131(3):234-9. (PMID: 26384790)
Clin Endocrinol (Oxf). 1980 Apr;12(4):363-9. (PMID: 6769612)
BMJ. 2000 Feb 26;320(7234):559-62. (PMID: 10688565)
Oncogene. 2009 May 14;28(19):2046-50. (PMID: 19363521)
Br J Cancer. 2011 Mar 15;104(6):921-6. (PMID: 21343929)
J Biol Chem. 2010 Jan 22;285(4):2676-85. (PMID: 19920132)
Mol Cell Endocrinol. 2016 Mar 15;424:94-101. (PMID: 26802879)
Open Heart. 2017 Apr 28;4(1):e000550. (PMID: 28674622)
Clin Endocrinol (Oxf). 1990 Feb;32(2):213-20. (PMID: 2112067)
Cancer Res. 1995 Aug 1;55(15):3331-8. (PMID: 7614468)
Cancer Prev Res (Phila). 2017 Jan;10(1):1-13. (PMID: 27965288)
Obstet Gynecol. 2014 Aug;124(2 Pt 1):300-306. (PMID: 25004350)
Am J Obstet Gynecol. 2011 Dec;205(6):518-25. (PMID: 21802066)
Gynecol Oncol. 2015 Aug;138(2):238-45. (PMID: 26013696)
Obstet Gynecol. 2005 Mar;105(3):575-80. (PMID: 15738027)
BMJ. 2007 Dec 1;335(7630):1134. (PMID: 17986716)
Am J Med. 2009 Jan;122(1 Suppl):S3-S14. (PMID: 19110086)
Cancer Control. 2009 Jan;16(1):14-22. (PMID: 19078925)
Endocrinology. 1996 Apr;137(4):1258-64. (PMID: 8625897)
J Clin Oncol. 2016 Dec 10;34(35):4225-4230. (PMID: 27903150)
Obstet Gynecol Int. 2013;2013:368543. (PMID: 24288542)
JAMA. 2011 Jun 8;305(22):2304-10. (PMID: 21642682)
J Endocrinol. 2010 Nov;207(2):237-43. (PMID: 20798131)
J Clin Endocrinol Metab. 2000 Jul;85(7):2402-10. (PMID: 10902785)
J Oncol. 2010;2010:139087. (PMID: 19884980)
Clin Genet. 2009 Jul;76(1):1-18. (PMID: 19659756)
J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34. (PMID: 12775774)
J Cancer Prev. 2013 Dec;18(4):313-21. (PMID: 25337560)
J Clin Endocrinol Metab. 2002 Jan;87(1):144-7. (PMID: 11788638)
Menopause. 2010 Jul;17(4):718-26. (PMID: 20216473)
J Clin Endocrinol Metab. 2003 Apr;88(4):1516-22. (PMID: 12679432)
Cancer Metastasis Rev. 2011 Mar;30(1):13-25. (PMID: 21271351)
معلومات مُعتمدة: P30 CA016672 United States CA NCI NIH HHS; P50 CA098258 United States CA NCI NIH HHS; R24 HD102061 United States HD NICHD NIH HHS; T32 CA101642 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: Lynch syndrome; endometrial cancer; obesity; premenopausal; prevention
سلسلة جزيئية: ClinicalTrials.gov NCT00500591
المشرفين على المادة: 0 (Biomarkers)
0 (Estrogens)
تواريخ الأحداث: Date Created: 20200825 Date Completed: 20210318 Latest Revision: 20220302
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC7897335
DOI: 10.1016/j.ajog.2020.08.053
PMID: 32835719
قاعدة البيانات: MEDLINE
الوصف
تدمد:1097-6868
DOI:10.1016/j.ajog.2020.08.053